The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Optimal Usage of Fecal Calprotectin for Intestinal Diseases

장질환에 있어서 Fecal Calprotectin의 적절한 사용

  • Kim, Eun Soo (Department of Internal Medicine, School of Medicine, Kyungpook National University)
  • 김은수 (경북대학교 의과대학 내과학교실)
  • Published : 2018.08.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001;7:460-465. https://doi.org/10.3748/wjg.v7.i4.460
  2. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426-431. https://doi.org/10.1136/gut.2005.069476
  3. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-798.
  4. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66. https://doi.org/10.1016/j.dld.2008.05.008
  5. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-813. https://doi.org/10.1111/j.1572-0241.2007.01126.x
  6. Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol 2015;6:14-19. https://doi.org/10.1136/flgastro-2013-100420
  7. Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20:1407-1415. https://doi.org/10.1097/MIB.0000000000000057
  8. Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013;19:1043-1052. https://doi.org/10.1097/MIB.0b013e3182807577
  9. Lasson A, Stotzer PO, Ohman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015;9:26-32.
  10. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-366. https://doi.org/10.1136/gut.45.3.362
  11. Meucci G, D'Inca R, Maieron R, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicenter prospective study. Dig Liver Dis 2010;42:191-195. https://doi.org/10.1016/j.dld.2009.07.002
  12. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369. https://doi.org/10.1136/bmj.c3369
  13. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-169. https://doi.org/10.1038/ajg.2009.545
  14. Taghvaei T, Maleki I, Nagshvar F, et al. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med 2015;10:321-328. https://doi.org/10.1007/s11739-014-1144-x
  15. Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 2015;110:802-819; quiz 820. https://doi.org/10.1038/ajg.2015.120
  16. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22. https://doi.org/10.1053/gast.2000.8523
  17. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70.e5; quiz e31. https://doi.org/10.1053/j.gastro.2011.09.034
  18. Molander P, Farkkila M, Ristimaki A, et al. Does fecal calprotectin predict short-term relapse after stopping $TNF{\alpha}$-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 2015;9:33-40.
  19. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010;4:144-152. https://doi.org/10.1016/j.crohns.2009.09.008
  20. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-1020.
  21. Molander P, af Bjorkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with $TNF{\alpha}$ blocking agents. Inflamm Bowel Dis 2012;18:2011-2017. https://doi.org/10.1002/ibd.22863
  22. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673-678. https://doi.org/10.1038/ajg.2008.119
  23. Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn's disease. Am J Gastroenterol 2015;110:865-872. https://doi.org/10.1038/ajg.2015.30
  24. Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006;10:17-22.